Chimeric Antigen Receptor-T Cell Therapies: Barriers and Solutions to Access

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Joseph Mikhael

Honoraria: Amgen, Karyopharm Therapeutics, Sanofi, Janssen, Takeda, Bristol Myers Squibb USA

Jessica Fowler

Employment: Janssen Oncology, Amgen

Stock and Other Ownership Interests: Amgen, Janssen Oncology

Nina Shah

Consulting or Advisory Role: Indapta Therapeutics, Sanofi, Oncopeptides, Karyopharm Therapeutics, Genentech/AbbVie, GlaxoSmithKline, Amgen, CareDX, Kite, a Gilead Company, CSL Behring

Research Funding: Celgene, Bluebird Bio, Janssen, Sutro Biopharma, Poseida Therapeutics, Nektar, Teneobio, Precision Biosciences, Cellectis

No other potential conflicts of interest were reported.